Assessing coronary artery disease with dipyridamole technetium-99m- tetrofosmin SPECT: A multicenter trial

Journal of Nuclear Medicine

Volumn 38, Issue 1, 1997, Pages 44-48

  He, Zuo Xiang ^a   Iskandrian, Ami S ^b   Gupta, Naresh C ^b   Verani, Mario S ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b NONE

Author keywords

coronary artery disease; dipyridamole; SPECT; technetium 99m tetrofosmin

Indexed keywords

DIPYRIDAMOLE; TETROFOSMIN TC 99M;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC IMAGING; HEART SCINTISCANNING; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASODILATATION;

ADULT; AGED; AGED, 80 AND OVER; CORONARY DISEASE; DIPYRIDAMOLE; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASODILATOR AGENTS;

EID: 0031030639     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Zaret BL, Wackers FJ. Nuclear cardiology. N Engl J Med 1993;329:775-783, 855-863.
2. 201Tl to regional myocardial perfusion. Circulation 1975;51:641-645.
3. 201Tl for myocardial perfusion imaging. J Nucl Med 1989;30:301-311.
4. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2{bis(2-ethoxyethyl)phosphine}ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993;34:30-38.
5. Kelly JD, Forster AM, Higley B, et al. Technetium-99m-tetrofosmin as a radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993;34:222-227.
6. Sinusas AJ, Shi QX, Saltzberg MT, et al. Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia J Nucl Med 1994;35:664-667.
7. 99mTc-tetrofosmin, myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med 1993;34:1254-1259.
8. 99mTc-tetrofosmin: stress-rest imaging with same-day and separate-day rest imaging. J Nucl Cardiol 1994;1:138-143.
9. 99mTc-tetrofosmin: comparison of one-day and two-day protocols. J Nucl Med 1994;1581-1585.
10. 201Tl imaging and coronary angiography in phase III multicenter trial. Circulation 1995;91:313-319.
11. 99mTc-sestamibi: comparison of dipyridamole versus exercise and of planar versus tomographic imaging. Nucl Med Commun 1993;14:946-954.
12. 201Tl SPECT in patients with left bundle branch block by dipyridamole. Am J Cardiol 1991;68:504-508.
13. 201Tl tomographic imaging for the detection of coronary artery disease using combined dipyridamole-exercise stress. Coron Artery Dis 1994; 5:787-791.
14. 201Tl scintigraphy for improved detection of left anterior descending coronary artery stenosis in patients with left bundle branch block. Eur Heart J 1993;14:53-56.
15. Machecourt J, Nenis B, Wolf JE, et al. Sensibilité et specificité respective de la scintigraphie myocardie realisée après injection de dipyridamole at au répos: comparison chex 70 subjects coronarographies. Arch Mal Coeur Vaiss 1981;74:147-156.
16. 201Tl: the significance of pharmacologic interventions. Jpn Cir J 1981;45:127-140.
17. Pezard P, Helias J, Victor J, et al. Thallium-201 myocardial scintigraphy and left branch block. Comparative value of exercise test and dipyridamole test. Arch Mal Coeur Vaiss 1993;86:1693-1699.
18. 201Tl perfusion defects in patients with coronary artery disease. Eur Heart J 1980;1:275-280.
19. Wilde P, Walker P, Watt I, et al. Thallium-201 myocardial imaging: recent experience with vasodilator. Clin Radiology 1982;33:43-50.
20. Mahmarian JJ, Verani MS. Myocardial perfusion imaging during pharmacologic stress testing. Cardiol Clin 1994;12:223-245.
21. 201Tl SPECT after oral dipyridamole for assessing the presence, anatomic location and severity of coronary artery disease. J Am Coll Cardiol 1988;11:962-969.
22. Maddahi J, Rodrigues E, Berman DS, Kiat H. State-of-the-art myocardial perfusion imaging. Cardiol Clin 1994;12:199-222.
23. 99mTc-sestamibi SPECT to characterize fixed myocardial defects as infarct or artifact. J Nucl Med 1995;36:952-955.
24. 201Tl in coronary artery disease. Am J Cardiol 1993;72:1015-1019.
25. 99mTc-tetrofosmin. J Nucl Cardiol 1994;1:29-38.
26. 99mTc-tetrofosmin to evaluate coronary artery disease. J Nucl Med 1994;35:594-660.
27. 201Tl and angiography. J Nucl Med 1994;35: 587-593.
28. 99mTc-tetrofosmin myocardial imaging for assessment of regional ventricular function: correlation with cinemagnetic resonance imaging [Abstract]. J Nucl Med 1995;36:135P-136P.
29. 99mTc-tetrofosmin imaging in humans. Ann Nuklearmedizin 1993;7:231-238.
30. Albro PC, Gould KL, Westcott RJ, et al. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacological coronary vasodilatation. III. Clinical trial. Am J Cardiol 1978;42:751-760.
31. 201Tl SPECT for the enhanced diagnosis of ischemic heart disease. J Am Coll Cardiol 1990;15:318-329.
32. 99mTc-tetrofosmin uptake during adenosine vasodilatation in a canine model of either critical or mild coronary stenosis [Abstract]. Circulation 1995;92:I-798.
33. 99mTc-hexakis 2-methoxy-2-isobutyl isonitrile (sestamibi) myocardial scintigraphy with high dose dipyridamole test in patients with effort angina pectoris: a multicenter study. J Am Coll Cardiol 1991;18:1439-1444.
34. 99mTc-MIBI SPECT. Circulation 1993;87:345-354.